Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Recent & Breaking News (NYSE:TAK)

BioLife Plasma Services Announces Opening of First Plasma Donation Center in New Jersey

Business Wire March 10, 2021

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio

Business Wire March 9, 2021

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Business Wire March 3, 2021

The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases

PR Newswire March 1, 2021

Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

Business Wire February 26, 2021

BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California

Business Wire February 24, 2021

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan

Business Wire February 24, 2021

Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement

Business Wire February 18, 2021

Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease

Business Wire February 12, 2021

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's Disease

Business Wire February 10, 2021

Rute Fernandes Appointed General Manager of Takeda Canada

Canada NewsWire February 8, 2021

Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

Business Wire February 4, 2021

Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Business Wire February 3, 2021

Takeda Completes Sale of TachoSil® to Corza Health

Business Wire February 1, 2021

Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

Business Wire January 29, 2021

Takeda Applies to Cease being a Reporting Issuer in Canada

Canada NewsWire January 28, 2021

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

Business Wire January 28, 2021

Takeda Achieved Carbon Neutrality in 2020

Business Wire January 27, 2021

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index

Business Wire January 26, 2021

Takeda Named Global Top Employer for Fourth Consecutive Year

Business Wire January 24, 2021